key: cord-0740946-50ick0ew
authors: Serre-Miranda, C.; Nobrega, C.; Roque, S.; Canto-Gomes, J.; Silva, C. S.; Vieira, N.; Barreira-Silva, P.; Alves-Peixoto, P.; Cotter, J.; Reis, A.; Formigo, M.; Sarmento, H.; Pires, O.; Carvalho, A.; Petrovykh, D. Y.; Dieguez, L.; Sousa, J. C.; Sousa, N.; Capela, C.; Palha, J. A.; Cunha, P. G.; Correia-Neves, M.
title: Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalized COVID-19 patients
date: 2020-08-07
journal: nan
DOI: 10.1101/2020.08.06.20168856
sha: 78ab9af168485b5f377fa93b9baa4814e5f79c88
doc_id: 740946
cord_uid: 50ick0ew

Commercial availability of serological tests to evaluate immunoglobulins (Ig) towards severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has grown exponentially since the onset of COVID-19 outbreak. Their thorough validation is of extreme importance before using them as epidemiological tools to infer population seroprevalence, and as complementary diagnostic tools to molecular approaches (e.g. RT-qPCR). Here we assayed commercial serological tests (semiquantitative and qualitative) from 11 suppliers in 126 samples collected from hospitalized COVID-19 patients, and from 36 healthy and HIV-infected individuals (collected at the pre-COVID-19 pandemic). Specificity was above 95% in 9 tests. Samples from COVID-19 patients were stratified by days since symptoms onset (<10, 10-15, 16-21 and >21 days). Tests sensitivity increases with time since symptoms onset, and peaks at 16-21 days for IgM and IgA (maximum: 91.2%); and from 16-21 to >21 days for IgG, depending on the test (maximum: 94.1%). Data from semiquantitative tests show that patients with severe clinical presentation have lower relative levels of IgM, IgA and IgG at <10 days since symptoms onset in comparison to patients with non-severe presentation. At >21 days since symptoms onset the relative levels of IgM and IgG (in one test) are significantly higher in patients with severe clinical presentation, suggesting a delay in the upsurge of Ig against SARS-CoV-2 in those patients. This study highlights the high specificity of most of the evaluated tests, and sensitivity heterogeneity. Considering the virus genetic evolution and population immune response to it, continuous monitoring of commercially available serological tests towards SARS-CoV-2 is necessary.

For sensitivity calculation, COVID-19 patients were stratified based on the number of days since symptoms onset as follows: <10 days; 10 to 15 days; 16 to 21 days; >21 days. Days since symptoms onset were calculated based on each patient's self-report of symptoms manifestation. COVID-19 patients were further categorized according to the severity of their clinical presentation. Patients given oxygen therapy above 10 L/min and/or needing mechanical ventilation (non-invasive or invasive) were considered as having a severe clinical presentation. All other patients (needing supplementary oxygen therapy below 10 L/min and not requiring mechanical ventilator support) were considered as having non-severe clinical presentation. SARS-CoV-2 non-infected controls were selected from banked human plasma samples from two studies at pre-COVID-19 pandemic (the first COVID-19 case in Portugal was reported in early March 2020): i) a study with healthy individuals older than 55 years of age (samples collected between April 2019 and January 2020); ii) a study with HIV-infected patients on antiretroviral therapy for 54 to 60 months (samples collected between January 2016 and August 2018) (24) . In both cases, matched samples were selected based on individuals' sex and age. Control samples were collected, processed and preserved at -80 ºC using a similar protocol as the one used for samples from COVID-19 inpatients (bellow). Data was handled anonymously. Individuals' sex, age and comorbidities are summarized in Table 1 . n/a n/a Neoplasia, n (%) 8 (9.0) 4 (12.5) 4 (7.0) n/a n/a Autoimmune disease, n (%) 5 (5.6) 2 (6.3) 3 (5.3) n/a n/a Immunosuppressive drugs, n (%) 5 (5.6) 3 (9.4) 2 (3.5) n/a n/a 1 Please see "Study Population" section on Methods.

n/a: not available Sample processing From each patient, venous blood was collected into K2EDTA collecting tubes and processed on the same day: blood collecting tubes were centrifuged at 2000g for 15 min, at 20 ºC. Plasma was aliquoted into screw-cap tubes and frozen at -80ºC until tested.

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 7, 2020. Table  S1 ). At least two different tests were performed for each sample (Supplementary Table S2, S3  and S4) .

For each test, specificity was calculated as the percentage of negative tests among the pre-COVID-19 controls, and sensitivity as the percentage of positive tests among the SARS-CoV-2 confirmed cases. Sensitivity was calculated upon stratification in days since symptoms onset (<10, 10-15; 16-21 and >21 days). Positive predictive value (PPV) was calculated as the proportion of true positive cases (i.e. positive serological test on confirmed SARS-CoV-2 infection by RT-qPCR) among the total positive tests, and the negative predictive value (NPV) as the proportion of true negative cases (i.e. negative serological test on pre-COVID-19 pandemic samples) among the total negative tests. Whenever the same patient was tested multiple times within the same time range during the course of the disease, only one plasma sample was considered to calculate sensitivity, PPV and NPV (Supplementary Table S2 ). The 95% confidence intervals for sensitivity, specificity, PPV and NPV were calculated using the Wilson score with continuity correction method. Tests agreement was evaluated using Cohen's Kappa. For the semiquantitative tests, receiver-operator characteristic (ROC) curves were constructed and used to calculate the area under the curve (AUC) of the different serologic tests. All variables analysed had a non-normal distribution, as verified by Shapiro-Wilk tests. Comparisons of the relative amounts of Ig at the various time ranges were performed using the Kruskal-Wallis test, followed by Dunn's post-hoc tests. Comparisons of the relative amount of Ig in the groups of patients with severe and non-severe clinical presentation were performed using the Mann-Whitney U test. Differences were considered significant when p <0.05. Statistical analyses were performed on GraphPad Prism version 8.4.3 (La Jolla, San Diego, CA, USA).

This study includes 89 hospitalized infected with SARS-CoV-2 (diagnosed by RT-qPCR). Plasma samples from 49 individuals were tested at a single timepoint, whereas 40 individuals were tested more than once during hospitalization (Supplementary Table S2 and S4). Most participants are women (57%; Table 1 ) with a median age of 71. None of the patients is positive for HIV nor was submitted to previous organ transplantation.

Serologic tests from 11 suppliers were assayed for their performance. Specificity considering IgM and IgG combined range from 76.0% (Cellex) to 100.0% (Liming and Render). Considering each Ig class independently, 4 out of 10 tests assessing IgG, and 5 out of 9 tests assessing IgA or IgM show 100.0% specificity ( Figure 1 and Table 2 ). Thirty-six samples were used as negative controls (collected during pre-COVID-19 pandemic); 10 negative controls are positive for at least 1 test; 5 of which tested positive in more than 1 test (Supplementary Table S3 ). As for the semiquantitative tests (Abbott, Euroimmun and Snibe), 2 of the negative control samples test positive in the Snibe IgG test and have a value close to the lower detection limit (1.124 and 1.652 AU/mL; cut-off 1.000 AU/mL; Supplementary Figure S1 ). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 7, 2020. . https://doi.org/10.1101/2020.08.06.20168856 doi: medRxiv preprint Figure 1 . Specificity and sensitivity of the assayed tests to detect immunoglobulins specific for SARS-CoV-2 infection. Sensitivity was evaluated in COVID-19 patients upon stratification by days since symptoms onset. Each dot represents the specificity or sensitivity, and bars represent the 95% confidence interval. n/a: not available. Ig: immunoglobulin. Figure 1 and Figure 2 ].

--- --- --- --- --- --- ------ --- --- --- ------ --- --- --- ------ --- --- --- ------ --- --- --- Innovita--- --- --- --- --- --- ------ --- --- --- ------ --- --- --- ------ --- --- --- ------ --- --- ------ --- --- --- --- --- ------ --- --- --- ------ --- --- --- ------ --- --- --- ------ --- --- --- Innovita--- --- --- --- --- --- ------ --- --- --- ------ --- --- --- ------ --- --- --- ------ --- --- ---

Overall, all the Ig assayed start being detected at early days since symptoms onset (<10 days). IgM and IgG reach the maximum relative amount at 16-20 days or at >21days. A peak of IgA detection is observed at 16-21 days since symptoms onset (Supplementary Figure S2) . To further investigate the association of Ig levels with clinical presentation, COVID-19 inpatients were classified as severe or non-severe, based on the need of supplementary oxygen or mechanic ventilatory support, as specified in the Methods section. The relative amount of Ig detected on each of the semiquantitative tests was compared between the two subgroups ( Figure 3 ). IgG relative amounts tend to be lower in the severe group at <10 days when compared with the non-severe group, reaching statistical significance for Abbot and Euroimmun is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 7, 2020. . https://doi.org/10.1101/2020.08.06.20168856 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 7, 2020. . https://doi.org/10.1101/2020.08.06.20168856 doi: medRxiv preprint Comparison of the Ig levels in patients with severe and non-severe clinical presentation using the semiquantitative tests Abbott, Euroimmun and Snibe. Each dot represents one sample, and the solid thick lines correspond to group's median. Solid thin lines represent each test's cut-off value. In the case of Euroimmun test, the shadowed grey banner refers to borderline values according to the manufacturer (between 0.8 and 1.1). Since the y-axis has a log scale that does not allow representation of zero, in those situations (Snibe IgG and IgM) arbitrary values were attributed, and a dashed grey line was represented in this value. For values above the detection limit (Euroimmun IgA), a random value of 20 was attributed and represented as a dashed grey line. Groups median were compared using a Mann-Whitney U-tests; significant differences were represented as: * for p < 0.05; ** for p < 0.01; ***, p < 0.001. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 7, 2020. . https://doi.org/10.1101/2020.08.06.20168856 doi: medRxiv preprint

Serological testing to SARS-CoV-2 infection is a rapid, inexpensive, and easy diagnostic approach complementary to RT-qPCR, but also an essential tool to access the presence and profile of Ig anti-SARS-CoV-2, both individually and at the population level. The present study compares the performance of serological tests towards SARS-CoV-2 using well characterized COVID-19 inpatients at various moments of the disease course, and with diverse clinical presentation severity. This study is relevant since most commercially available tests emerged in the market soon after the COVID-19 outbreak and were based on the analysis of a limited number of patients. In the recent months, many studies exploring the production of Ig against SARS-CoV-2 have been reported, but few compare several tests between them using the same set of plasma samples. Comparison of tests performance, as presented here, is of relevance since it depends on inherent population genetic variations, on time during course of the disease and on disease severity. Irrespective of the test methodology (ELISA, CLIA, LFIA), we observe here, as reported previously, that test sensitivity is dependent on time since symptoms onset. In addition, the combined detection of IgG and IgA/IgM against SARS-CoV-2 leads, in most cases, to a better performance than measurements of a single Ig class, regardless of the time range evaluated. These observations were previously reported by others, and are in agreement with the establishment of the immune response, where IgA, IgM and IgG have different dynamics throughout disease progression (5, (12) (13) (14) (15) (16) (17) (18) 25) . This dynamic nature of tests sensitivity needs to be considered when interpreting performance. Inconsistent reporting by manufactures, or lack of details about the timepoints used to establish tests' performance, caused confusion about the expected sensitivity. This has contributed to the recent decision by the US Food and Drug Administration to remove some tests from the Emergency Use Authorization. Previous reports concluded that N-protein/peptide-based tests present better sensitivities than the ones based on S-protein/peptide. This difference may result from an earlier immune response towards the N-protein/peptide in comparison to the one towards the S-protein/peptide, or related to the higher specificity of Ig towards the N-protein/peptide (26) (27) (28) . It is not possible to confront these previous results with ours, as 4 of the assayed tests displayed no information regarding the target antigen, 4 target both proteins, 2 target only the N-protein/peptide alone; and 1 target only the S-protein.

Regarding seroconversion rate, it is striking to notice that Ig anti-SARS-CoV-2 are detectable at very early days since symptoms onset (at 3 to 5 days either for IgM, IgA or IgG; e.g. Patients 012, 033 and 070; Supplementary Table S2) , though for others, detection using the same tests occurs only much later (>21 days; e.g. Patients 004, 037 and 064; Supplementary Table S2) . Several factors might account for these observations. Antibody production kinetics during SARS-CoV-2 infection is not yet fully elucidated, nor are the factors responsible for differences in patients' response. As others suggested previously (17, 18) , we also observe that patients with non-severe clinical presentation show higher relative amounts of IgG, IgA and IgM at the earlier period since symptoms onset. Identifying the variable responsible for distinct profiles of seroconversion is necessary to be able to fully understand false-negative results. It is important to recall that the time since symptoms onset is self-reported, which might introduce variability taking into consideration the diversity of clinical manifestation of COVID-19 and of symptoms perception by each individual. However, we consider that it introduces less variability than time since disease diagnosis, which is performed for some patients before symptoms onset and for others several days after. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 7, 2020. . https://doi.org/10.1101/2020.08.06.20168856 doi: medRxiv preprint Due to the high specificity of most of the assayed tests, their PPV are relatively high (over 90%). Individuals with positive serodiagnosis tests have a high likelihood of being infected by SARS-CoV-2 (past or present infection). However, a negative serologic test in these settings should not be interpreted as not being infected with SARS-CoV-2 as the NPV are relatively low (38% to 68%). Our results highlight that Ig levels, on a hospitalized COVID-19 population, depend on disease severity. In fact, our data suggests a delay in Ig detection in patients with worse disease presentation; they present lower relative amounts of Ig at the initial phase of the disease and higher at later stages, in comparison to patients with non-severe clinical presentation. This information is of outmost relevance in clinical settings and needs to be further explored in a larger cohort of patients evaluated longitudinally, since the very beginning of symptoms manifestation perception, and throughout longer time-periods. Our results are based on measurements performed in a specific population of hospitalized COVID-19 patients and should not be extrapolated to the general population. Still, it provides the basis for an informed selection of a serological test to be assayed and applied in a greater population setting to evaluate the potential value of each test as a complement for COVID-19 diagnosis and to understand the dynamics of Ig production upon infection with SARS-CoV-2.

This work was funded by National funds, through the Foundation for Science and Technology (FCT): R4COVID (596694995), POCI-01-0145-FEDER-016428, UIDB/50026/2020 and UIDP/50026/2020; and by the projects NORTE-01-0145-FEDER-000013 and NORTE-01-0145-FEDER-000023, supported by Norte Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 7, 2020. . https://doi.org/10.1101/2020.08.06.20168856 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 7, 2020. . https://doi.org/10.1101/2020.08.06.20168856 doi: medRxiv preprint

WHO Director-General's opening remarks at the media briefing on COVID-19 -11

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Early Spread of SARS-Cov-2 in the Icelandic Population

Detection of 2019 novel coronavirus ( 2019-nCoV ) by real-time RT-PCR

Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)

Antibody Responses to SARS-CoV-2 in Patients of Novel Coronavirus Disease

Structure , Function , and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

The hallmarks of COVID-19 disease

Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients

Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies

Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients

Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease

IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study

Longitudinal Change of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in Patients with Coronavirus Disease

Patterns of IgG and IgM antibody response in COVID-19 patients

Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients

Herd Immunity : Understanding COVID-19

Comparison of the Elecsys ® Anti-SARS-CoV-2 immunoassay with the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 antibodies in human plasma

Performance of SARS-CoV-2 antibody assays in different stages of the infection: Comparison of commercial ELISA and rapid tests

Serology testing in the COVID-19 pandemic response

Implication of SARS-CoV-2 evolution in the sensitivity of RT-qPCR diagnostic assays

Thymic fuction as a predictor of immune recovery in chronically HIV-infected patients initiating antiretreoviral therapy

Test performance evaluation of SARS-CoV-2 serological assays

Meta-analysis of diagnostic performance of serological tests for SARS-CoV-2 antibodies up to 25 April 2020 and public health implications

Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2